Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells

Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells

The genetic principle of synthetic lethality has most successfully been exploited in therapies engaging Poly-ADP-ribose-polymerase (PARP) inhibitors to treat patients with homologous recombination (HR)-defective tumors. In this work, we went a step further following the idea of a local molecular coo...

Full description

Bibliographic Details
Main Authors: Matthews M. Malka, Julia Eberle, Kathrin Niedermayer, Darius P. Zlotos, Lisa Wiesmüller
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Biomolecules
Subjects:
PARP inhibitor
Olaparib
RAD51 inhibitor
drug conjugates
anticancer drug hybrids
triple-negative breast cancer
Online Access:https://www.mdpi.com/2218-273X/11/7/981

Similar Items

Similar Items